Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2013 1
2014 3
2015 8
2016 22
2017 35
2018 38
2019 23
2020 15
2021 19
2022 12
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29653975

157 results

Results by year

Filters applied: . Clear all
Page 1
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen.
Huang K, Schatka I, Rogasch JMM, Lindquist RL, De Santis M, Erber B, Radojewski P, Brenner W, Amthauer H. Huang K, et al. Ann Nucl Med. 2021 Mar;35(3):314-320. doi: 10.1007/s12149-020-01567-3. Epub 2020 Dec 22. Ann Nucl Med. 2021. PMID: 33351172 Free PMC article.
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Heck MM, et al. J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8. J Urol. 2016. PMID: 26964917
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ, Niaz MJ, Skafida M, Mosallaie SA, Thomas C, Christos PJ, Osborne JR, Molina AM, Nanus DM, Bander NH, Tagawa ST. Vlachostergios PJ, et al. Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19. Prostate. 2021. PMID: 33465252 Free PMC article. Clinical Trial.
The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?
Basu S, Parghane RV, Joshi A, Prabhash K, Banerjee S. Basu S, et al. Nucl Med Commun. 2018 Dec;39(12):1061-1063. doi: 10.1097/MNM.0000000000000932. Nucl Med Commun. 2018. PMID: 30339554 No abstract available.
157 results